These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 26430247)

  • 21. Therapy Optimization in Multiple Sclerosis: a cohort study of therapy adherence and risk of relapse.
    Cohen BA; Coyle PK; Leist T; Oleen-Burkey MA; Schwartz M; Zwibel H
    Mult Scler Relat Disord; 2015 Jan; 4(1):75-82. PubMed ID: 25787057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [New active substances expand the treatment options for MS].
    Hellwig B
    Med Monatsschr Pharm; 2015 Feb; 38(2):65-8. PubMed ID: 26376542
    [No Abstract]   [Full Text] [Related]  

  • 23. Short-term suboptimal response criteria for predicting long-term non-response to first-line disease modifying therapies in multiple sclerosis: A systematic review and meta-analysis.
    Río J; Ruiz-Peña JL
    J Neurol Sci; 2016 Feb; 361():158-67. PubMed ID: 26810535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients.
    Johnson BH; Bonafede MM; Watson C
    CNS Drugs; 2015 Jun; 29(6):503-10. PubMed ID: 26113055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Different clinical response to interferon beta and glatiramer acetate related to the presence of oligoclonal IgM bands in CSF in multiple sclerosis patients.
    Casanova B; Lacruz L; Villar ML; Domínguez JA; Gadea MC; Gascón F; Mallada J; Hervás D; Simó-Castelló M; Álvarez-Cermeño JC; Calles C; Olascoaga J; Ramió-Torrentà L; Alcalá C; Cervelló A; Boscá I; Pérez-Mirallles FC; Coret F
    Neurol Sci; 2018 Aug; 39(8):1423-1430. PubMed ID: 29882169
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-Effectiveness Modeling in Multiple Sclerosis: Playing Around with Non-Healthcare Costs?
    Garattini L; Ghislandi F; Da Costa MR
    Pharmacoeconomics; 2015 Dec; 33(12):1241-4. PubMed ID: 26293887
    [No Abstract]   [Full Text] [Related]  

  • 27. [Immunomodulatory effects of glatiramer acetate as they relate to stage-specific immune dysregulation in multiple sclerosis].
    Yokoyama K; Hattori N
    Nihon Yakurigaku Zasshi; 2016 Aug; 148(2):105-20. PubMed ID: 27478050
    [No Abstract]   [Full Text] [Related]  

  • 28. Relations between mood characteristics, circadian preferences, and functionality in multiple sclerosis.
    Ozdemir PG; Milanlioglu A; Boysan M; Cilingir V; Aydin N; Atli A
    Int J Psychiatry Clin Pract; 2015 Jun; 19(2):148-54. PubMed ID: 25363199
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Problems and prospects of beta-interferon and copaxone++ application in the treatment of multiple sclerosis].
    Gusev EI; Boĭko AN; Pozer Ch
    Zh Nevrol Psikhiatr Im S S Korsakova; 1999; 99(4):33-6. PubMed ID: 10319395
    [No Abstract]   [Full Text] [Related]  

  • 30. Confusion over UK beta-interferon "trials".
    Dean M
    Lancet; 2001 Nov; 358(9293):1619. PubMed ID: 11716901
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmacoeconomic modeling of drug therapies for multiple sclerosis--are we building houses on sand?
    Curtiss FR
    J Manag Care Pharm; 2007 Apr; 13(3):287-9. PubMed ID: 17407397
    [No Abstract]   [Full Text] [Related]  

  • 32. Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis.
    Zhang T; Tremlett H; Leung S; Zhu F; Kingwell E; Fisk JD; Bhan V; Campbell TL; Stadnyk K; Yu BN; Marrie RA;
    Neurology; 2016 Apr; 86(14):1287-1295. PubMed ID: 26944268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NICE and drugs for multiple sclerosis. National Institute of Clinical Excellence.
    Hartung HP
    Lancet; 2000 Sep; 356(9235):1114. PubMed ID: 11009171
    [No Abstract]   [Full Text] [Related]  

  • 34. Comment on Shuhaibar et al.: Favourable effect of immunomodulator therapy on bone mineral density in multiple sclerosis.
    Kampman MT; Steffensen LH
    Ir J Med Sci; 2009 Jun; 178(2):235-6; author reply 237-8. PubMed ID: 19184608
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacogenetics of multiple sclerosis: personalized therapy with immunomodulatory drugs.
    Tsareva E; Kulakova O; Boyko A; Favorova O
    Pharmacogenet Genomics; 2016 Mar; 26(3):103-15. PubMed ID: 26678572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Disease modifying drugs in multiple sclerosis and pregnancy].
    Tur C; Tintoré M; Aguilera C
    Med Clin (Barc); 2012 Sep; 139(7):316-8. PubMed ID: 22743277
    [No Abstract]   [Full Text] [Related]  

  • 37. Immunomodulatory treatment of multiple sclerosis in Norway.
    Torkildsen Ø; Grytten N; Myhr KM
    Acta Neurol Scand Suppl; 2007; 187():46-50. PubMed ID: 17419828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short- and long-term clinical outcomes of use of beta-interferon or glatiramer acetate for people with clinically isolated syndrome: a systematic review of randomised controlled trials and network meta-analysis.
    Armoiry X; Kan A; Melendez-Torres GJ; Court R; Sutcliffe P; Auguste P; Madan J; Counsell C; Clarke A
    J Neurol; 2018 May; 265(5):999-1009. PubMed ID: 29356977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The pegylated form of interferon beta in the treatment of multiple sclerosis].
    Melnikov MV; Kasatkin DS; Volkov AI; Boyko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(8):136-141. PubMed ID: 31626182
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concomitant therapy for multiple sclerosis.
    Stuart WH; Vermersch P
    Neurology; 2004 Dec; 63(11 Suppl 5):S28-34. PubMed ID: 15596733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.